Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Drug Repositioning Service Market Size, Value And Growth Trajectory Through 2030
The drug repositioning service market has seen substantial expansion in recent years. It is anticipated to increase from $34.2 billion in 2025 to $36.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be linked to factors like the rising costs of pharmaceutical R&D, the wealth of available legacy drug data, an uptick in unsuccessful clinical trials, the escalating need for quicker drug development cycles, and the early embrace of computational drug discovery.
The drug repositioning service market is projected to experience robust expansion over the coming years. This market is forecast to reach $45.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.1%. Several factors are expected to drive this growth during the forecast period, including a heightened demand for economical drug development, the increasing integration of AI-driven discovery solutions, a sharpened focus on rare and orphan conditions, the broadening scope of data-intensive clinical research, and a greater regulatory embrace of drugs that have been repurposed. Key trends anticipated throughout this period involve the wider deployment of AI-powered drug repurposing platforms, an elevated emphasis on re-evaluating drugs that failed in clinical trials, the expanding incorporation of real-world evidence into drug discovery processes, the diversification of precision medicine-focused repositioning efforts, and strengthened partnerships between pharmaceutical companies and contract research organizations (CROs).
Get A Free Sample Report With In-Depth Market Insights:
Drug Repositioning Service Market Demand Drivers Opening New Revenue Streams
The anticipated expansion of the drug repositioning service market is linked to an increase in healthcare expenditures. These expenditures encompass the total funds allocated to health services, covering prevention, treatment, rehabilitation, and administrative functions. The rise in healthcare spending is primarily driven by escalating medical costs, which are influenced by technological advancements and the growing demand for healthcare provisions. Higher healthcare expenditure benefits drug repositioning services because enhanced funding facilitates more clinical trials and research, thus accelerating the identification of new therapeutic applications for existing drugs. For instance, according to the Office for National Statistics, a UK-based Government department, in May 2024, total healthcare expenditure experienced a significant 5.6% nominal rise from 2022 to 2023. Consequently, the uptick in healthcare expenditures is propelling the growth of the drug repositioning service market.
Drug Repositioning Service Market Segment Analysis And Revenue Potential
The drug repositioning service market covered in this report is segmented –
1) By Type: Generic Drugs, Clinical Trial Failed Drugs
2) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Other Therapeutic Area
3) By End-User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic Research Institutions, Hospitals And Ambulatory Surgical Centers.
Subsegments:
1) By Generic Drugs: Small Molecule Drugs, Biologics, Biosimilars, Peptide-Based Drugs
2) By Clinical Trial Failed Drugs: Phase I Failed Drugs, Phase II Failed Drugs, Phase III Failed Drugs, Safety-Related Failed Drugs, Efficacy-Related Failed Drugs
Drug Repositioning Service Market Trends Powering Strategic Industry Growth
Leading companies in the drug repositioning service market are prioritizing the integration of artificial intelligence (AI) in drug repositioning, including the use of computational drug repositioning systems. These systems systematically uncover new therapeutic uses for existing drugs through AI-powered analysis of scientific literature and biological data. A computational drug repositioning system functions as a technology-driven platform, employing artificial intelligence, machine learning, and data mining to methodically scrutinize existing drugs, compounds, and biological information. For instance, in November 2024, Japanese firms UBE and FRONTEO initiated a co-creation project. This collaborative framework combines the specialized knowledge of both UBE and FRONTEO to bolster drug repositioning endeavors. It fosters smooth interaction between data analysis (dry research) and biological testing (wet research), thereby improving the progression from initial hypothesis formulation to experimental confirmation. By leveraging FRONTEO’s AI-driven Drug Discovery AI Factory and KIBIT technology, the project aims to systematically identify previously unrecorded connections between diseases and molecules.
Drug Repositioning Service Market Key Players Shaping Industry Direction
Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited
View The Full Drug Repositioning Service Market Report:
Drug Repositioning Service Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the drug repositioning service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repositioning service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
